Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine (DFMO) vs Placebo in Low Grade Superficial Bladder Cancer
NCT00003814Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eflornithine in bladder cancer, sponsored by National Cancer Institute. Started Feb 1999; status: completed.
02
Drugs
eflornithine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00003814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003814.